GEDAL NOTES
D.24 | JNJ / April 2026
By zachgedal
Published on April 13, 2026
in Uncategorized
Comprehensive Equity and Dividend Analytics Review: Johnson & Johnson (JNJ) – April 2026
Hey fellow investors,
As we roll into the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) feels like it’s at one of those classic “end of one era, start of the next” moments. The company has now fully completed the spin-off of its Kenvue consumer health business, so it’s operating as a pure-play healthcare powerhouse focused only on Innovative Medicine (pharma) and Medical Technology (MedTech). I put together this deep-dive review during the week of April 9, 2026, to really unpack the stock’s equity story, dividend durability, valuation, balance sheet strength, and all the challenges it’s facing right now.
At Friday’s close on April 10, 2026, JNJ shares sat at $238.46 (after opening around $242). That gives the company a market cap of roughly $581.23 billion. The last 30 trading days saw a tiny 1.79% dip in market cap, but over the full trailing twelve months the enterprise value is still up a solid 16.57%. The 52-week range runs from a low of $146.12 all the way up to an all-time high of $251.71 hit in early March 2026. So yeah — the stock has had some volatility, but it’s still trading near the top of its recent range.
For income investors and institutions alike, the biggest magnet is still JNJ’s legendary dividend. The current quarterly payout is $1.30 per share, which annualizes to $5.20 and gives you about a 2.18% yield at current prices. It might not look sky-high compared to some other yields out there, but the real magic is in the consistency: this is a Dividend King with 63 straight years of dividend increases. That kind of track record is incredibly rare.
Of course, a good dividend story alone isn’t enough anymore. In 2025 the company posted $94.19 billion in revenue (6.0% growth) and generated a massive $20.418 billion in free cash flow. That cash machine gives management tons of flexibility. But they’re also dealing with the Stelara patent cliff, big-ticket acquisitions (the $14.6B Intra-Cellular Therapies deal and $3B Halda Therapeutics buy), and the ongoing multi-billion-dollar talcum powder litigation mess with more than 67,000 federal claims still hanging over them.
This post walks through all of it — dividend safety, valuation, operations, risks, and what to watch for in the upcoming Q1 earnings on April 14. Let’s dig in.
Dividend Profile, Distribution Architecture, and Yield Analytics
At its core, the case for owning JNJ is built on a rock-solid, growing, inflation-fighting dividend. That reliability is what makes the stock such a defensive anchor for so many portfolios.
Recent Declaration Mechanics and Historical Context
The payout stayed steady at $1.30 in Q1 2026. The board declared it on January 2, 2026; ex-dividend and record date were both February 24; payment hit accounts on March 10. That’s the fourth quarter in a row at this level (it stepped up from $1.24 earlier in 2025).
Here’s the recent declaration history for easy reference:
| Declaration Date | Ex-Dividend Date | Record Date | Payable Date | Amount per Share | Frequency |
|---|---|---|---|---|---|
| January 2, 2026 | February 24, 2026 | February 24, 2026 | March 10, 2026 | $1.30 | Quarterly |
| October 14, 2025 | November 25, 2025 | November 25, 2025 | December 9, 2025 | $1.30 | Quarterly |
| July 16, 2025 | August 26, 2025 | August 26, 2025 | September 9, 2025 | $1.30 | Quarterly |
| April 15, 2025 | May 27, 2025 | May 27, 2025 | June 10, 2025 | $1.30 | Quarterly |
| January 2025 | February 18, 2025 | February 18, 2025 | March 4, 2025 | $1.24 | Quarterly |
| October 2024 | November 26, 2024 | November 26, 2024 | December 10, 2024 | $1.24 | Quarterly |
Trailing twelve-month dividends now total $5.20 per share, giving that 2.18% forward yield. Most of us expect the next move — the 64th consecutive annual increase — to be announced alongside Q1 earnings on April 14.
Total Shareholder Yield: Dividends, Repurchases, and Debt Optimization
Dividend yield is only part of the story. When you add share buybacks and smart debt management you get the full “Total Shareholder Yield.” JNJ has been steadily ramping up its buyback program: 0.51% yield in 2023 → 0.68% in 2024 → 0.87% in 2025, and analysts see it crossing 1.01% in 2026. Stack that on top of the 2.18% dividend yield and you’re looking at roughly 3.19% total shareholder yield. That’s a nice psychological floor under the stock.
Dividend Growth Trajectory and Compounding Mechanics
Dividend growth has naturally slowed as the company has gotten bigger and more focused, but it’s still very healthy. Here’s the compound annual growth rate (CAGR) breakdown:
- 10-year: 5.65% – 5.71%
- 5-year: 5.18% – 5.25%
- 3-year: 4.78% – 4.92%
- 1-year (2024→2025): 4.68%
This gradual deceleration isn’t a red flag — it’s management being prudent after the Kenvue spin-off. The remaining businesses have higher margins but also more volatility from patent cliffs and clinical trials, so they’ve calibrated growth to stay sustainable.
Yield on Cost (YOC) Projections and Long-Term Value Creation
Here’s where it gets exciting for long-term holders. If you buy around $240 today and dividends keep growing at a conservative ~5.4% annually, your effective yield on cost should look something like this:
- 2026: $5.42 – $5.44 → 2.25% – 2.26% YOC
- 2027: $5.71 – $5.76 → 2.37% – 2.39%
- 2028: $6.01 – $6.10 → 2.49% – 2.53%
- 2029: $6.33 – $6.46 → 2.63% – 2.68%
- 2030: $6.71 – $6.84 → 2.78% – 2.84%
- 2032: $7.46 – $7.67 → 3.09% – 3.18%
- 2035: $8.76 – $9.10 → 3.63% – 3.77%
In plain English: someone buying today could be earning north of 3.7% on their original cost basis in ten years — all while the dividend keeps compounding.
Coverage Diagnostics: Free Cash Flow and Payout Ratio Mechanics
Safety first. The two key payout ratios both look very comfortable.
Net Earnings View
2025 adjusted net earnings: $26.215 billion ($10.79 diluted EPS).
Dividend payout ratio = ~48.19%.
Plenty of room left for R&D, acquisitions, and debt service. Gross margin 67.88%, operating margin 34.59%, EBITDA margin 44.71%, and ROE hit 32.87% — strong profitability.
Free Cash Flow View (the stricter test)
2025 FCF: $20.418 billion (only a tiny -0.48% dip from 2024).
Dividends paid: ~$12.4 billion.
FCF payout ratio = 60.73%.
That leaves nearly $8 billion in surplus cash flow every year after the dividend. The company converts about 20.9% of revenue straight into free cash flow — elite efficiency.
Here’s the recent FCF history:
| Fiscal Year | Annual Free Cash Flow | YoY Change |
|---|---|---|
| 2025 | $20.418 Billion | -0.48% |
| 2024 | $20.517 Billion | +10.27% |
| 2023 | $18.606 Billion | +4.95% |
| 2022 | $17.728 Billion | -13.39% |
| 2021 | $20.469 Billion | -0.12% |
Fundamental Valuation Multiples and Intrinsic Pricing
JNJ isn’t cheap, but it’s not wildly expensive either when you look at the quality.
Comparative Multiples (April 2026)
| Valuation Multiple | JNJ | Novartis (NVS) | AbbVie (ABBV) |
|---|---|---|---|
| Price/Earnings (Normalized) | 22.08x | 17.15x | 20.79x |
| Price/Book Value | 7.04x | 6.37x | N/A |
| Price/Sales | 6.15x | 5.31x | 6.03x |
| Price/Cash Flow | 15.55x | 14.53x | 17.23x |
Investors are paying a premium for JNJ’s stability and dividend fortress.
Intrinsic DCF Perspective
Using a simple Gordon Growth Model (forward dividend $5.44, 5.2% terminal growth, 7.5% required return) I get a fair value around $236.50. More detailed multi-stage DCF models used by institutions land near $241.71. At $238.46 the stock is basically trading right at fair value — a “Hold / Accumulate” for long-term dividend investors, not a screaming bargain but still very reasonable.
Capital Structure, Liquidity, and Balance Sheet Integrity
JNJ used to be an AAA-rated balance-sheet king. It’s still rock-solid, but debt has climbed to fund big acquisitions.
End of 2025:
- Total assets $199.21B
- Total liabilities $117.7B
- Shareholder equity $81.5B (up 14.1% YoY)
- Long-term debt $39.4B (up 28.7% from 2024)
Net debt after cash is around $28B — very manageable for a company this size. Interest coverage is a massive 33.47x, so debt service is no threat to the dividend. Current/quick ratios look tight (1.03 / 0.77), but that’s intentional efficient cash management, not distress.
Operational Diagnostics: The Dual-Engine Growth Model
Innovative Medicine (Pharma) – ~64% of revenue ($60.4B in 2025, +5.3%)
Oncology is the star: Darzalex alone is a $14B+ franchise growing fast, and management wants to be the #1 oncology player globally with $50B in annual oncology sales by 2030. Immunology is the pain point — Stelara sales crashed 48% in Q4 2025 because of biosimilars — but Tremfya is stepping up nicely. Big M&A (Intra-Cellular, Halda, Ambrx) is helping refill the pipeline.
Medical Technology – ~36% of revenue ($33.8B in 2025, +5.4%)
Cardiovascular (especially Shockwave’s IVL technology) and the upcoming Ottava robotic surgery platform are the big growth bets here. MedTech gives JNJ a nice lower-volatility counterbalance to pharma’s binary risks.
Macroeconomic Headwinds and Enterprise-Level Risks
Two big clouds:
- Drug pricing pressure (Inflation Reduction Act, Medicare Part D changes, possible tariffs/MFN pricing).
- The talcum powder litigation — still the single biggest valuation drag. Over 67,376 federal claims. The “Texas Two-Step” bankruptcy strategy failed, so the company is back in front of juries. Recent verdicts have been huge (though many get reduced on appeal). Analysts think a global settlement could cost $9–11B spread over years — manageable with $20B+ annual FCF, but the uncertainty keeps the P/E multiple capped.
Q1 2026 Earnings Anticipation and Forward Catalysts
Earnings drop pre-market on Tuesday, April 14.
Consensus: Revenue $23.44B – $23.60B (+6.8% YoY), EPS $2.68.
Full-year 2026 guidance eyes $100B+ in revenue for the first time ever and EPS around $11.54.
Most importantly for dividend investors: history says the annual dividend increase will be announced that same day. Models point to a bump from $1.30 to roughly $1.36 quarterly (annualizing to $5.44).
Strategic Conclusion
JNJ today is a high-margin, cash-gushing, dual-engine healthcare machine that just crossed the $94B revenue mark and still throws off over $20B in free cash flow. The dividend is ironclad, the buyback program is accelerating, and the long-term growth engines (oncology, Tremfya, Shockwave, Ottava robotics) look promising.
The stock isn’t a deep-value screaming buy at $238, but it’s trading right around intrinsic value and offers a reliable 2.18% yield with a clear path to 3.5%+ yield-on-cost over the next decade. The only real anchor on the multiple is the litigation overhang. Once that’s finally quantified and settled, I suspect the stock can finally breathe and deliver the kind of multiple expansion income investors have been waiting for.
For patient, long-term dividend growth portfolios, JNJ remains one of the very best foundational holdings out there. If you’re accumulating below $240, you’re locking in an excellent long-run compounding machine.
I’ll be watching the April 14 earnings and dividend announcement closely — expect a quick follow-up if anything surprises us.
Stay invested, stay patient, and keep learning.
— zachgedal
Works cited (same sources as the original research note — all accessed April 12, 2026 via the links provided in the detailed analysis).
Hey there, fellow investor!
(If you’re new around here, welcome! This is where I break down dividend stocks, portfolio updates, and long-term investing ideas in plain English. Hit follow and let’s build some wealth together.)
Ready for the next one? I’ve already got the Kroger (KR) deep-dive teed up for later this month. Let me know in the comments what you think of the JNJ story — buy, hold, or wait for a better entry? 🚀
